Combinations and modes of administration of therapeutic agents and combination therapy
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-047/48
A61K-031/517
A61K-031/395
A61K-009/14
A61K-009/00
A61K-009/51
A61K-031/282
A61K-031/337
A61K-031/555
A61K-031/7068
A61K-031/7072
A61K-033/24
A61K-038/38
A61K-045/06
A61K-031/165
A61K-031/436
A61K-031/519
A61K-031/5377
A61K-031/675
A61K-031/69
A61K-031/704
A61K-038/16
A61K-039/395
A61N-005/10
A61K-047/42
출원번호
US-0585696
(2012-08-14)
등록번호
US-9101543
(2015-08-11)
발명자
/ 주소
Desai, Neil P.
Soon-Shiong, Patrick
출원인 / 주소
ABRAXIS BIOSCIENCE, LLC
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
20인용 특허 :
76
초록▼
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radi
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
대표청구항▼
1. A method of treating pancreatic cancer in a human individual in need thereof, comprising intravenously administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with albumin, wherein the average diameter of the nanoparticles in
1. A method of treating pancreatic cancer in a human individual in need thereof, comprising intravenously administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with albumin, wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm, and b) an effective amount of gemcitabine. 2. The method of claim 1, wherein the nanoparticle composition and the gemcitabine are administered sequentially to the individual. 3. The method of claim 2, wherein the nanoparticle composition is administered before the administration of gemcitabine. 4. The method of claim 1, wherein the nanoparticle composition and the gemcitabine are both administered weekly to the individual. 5. The method of claim 1, wherein the nanoparticle composition and the gemcitabine are administered three out of four weeks to the individual. 6. The method of claim 1, wherein the method comprises administering about 30 to about 300 mg/m2 paclitaxel in a nanoparticle composition to the individual. 7. The method of claim 6, wherein the method comprises administering about 50 to about 250 mg/m2 paclitaxel in a nanoparticle composition to the individual. 8. The method of claim 7, wherein the method comprises administering about 100 to about 150 mg/m2 paclitaxel in a nanoparticle composition to the individual. 9. The method of claim 8, wherein the method comprises administering about 125 mg/m2 paclitaxel in a nanoparticle composition to the individual. 10. The method of claim 8, wherein the method comprises administering about 1000 to about 2000 mg/m2 gemcitabine to the individual. 11. The method of claim 1, wherein the albumin is human serum albumin. 12. The method of claim 11, wherein the weight ratio of the albumin and the paclitaxel in the nanoparticle composition is about 1:1 to about 18:1. 13. The method of claim 12, wherein the weight ratio of the albumin and the paclitaxel in the nanoparticle composition is about 2:1 to about 15:1. 14. The method of claim 13, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 4:1 to about 10:1. 15. The method of claim 14, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 9:1. 16. The method of claim 1, wherein the nanoparticles composition is sterile filterable. 17. The method of claim 1, wherein the weight ratio of the albumin and the paclitaxel in the nanoparticle composition is about 1:1 to about 18:1. 18. The method of claim 17, wherein the weight ratio of the albumin and the paclitaxel in the nanoparticle composition is about 2:1 to about 15:1. 19. The method of claim 18, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 4:1 to about 10:1. 20. The method of claim 19, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 9:1. 21. The method of claim 1, wherein the pancreatic cancer is metastatic pancreatic cancer. 22. The method of claim 21, wherein the nanoparticle composition and the gemcitabine are administered sequentially to the individual. 23. The method of claim 22, wherein the nanoparticle composition is administered before the administration of gemcitabine. 24. The method of claim 23, wherein the method comprises administering about 30 to about 300 mg/m2 paclitaxel in a nanoparticle composition to the individual. 25. The method of claim 24, wherein the method comprises administering about 50 to about 250 mg/m2 paclitaxel in a nanoparticle composition to the individual. 26. The method of claim 25, wherein the method comprises administering about 100 to about 150 mg/m2 paclitaxel in a nanoparticle composition to the individual. 27. The method of claim 26, wherein the method comprises administering about 125 mg/m2 paclitaxel in a nanoparticle composition to the individual. 28. The method of claim 27, wherein the method comprises administering about 1000 to about 2000 mg/m2 gemcitabine to the individual. 29. The method of claim 28, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 4:1 to about 10:1. 30. The method of claim 29, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 9:1. 31. The method of claim 23, wherein the nanoparticle composition and the gemcitabine are administered three out of four weeks to the individual. 32. The method of claim 21, wherein the method comprises administering about 30 to about 300 mg/m2 paclitaxel in a nanoparticle composition to the individual. 33. The method of claim 32, wherein the method comprises administering about 50 to about 250 mg/m2 paclitaxel in a nanoparticle composition to the individual. 34. The method of claim 33, wherein the method comprises administering about 100 to about 150 mg/m2 paclitaxel in a nanoparticle composition to the individual. 35. The method of claim 34, wherein the method comprises administering about 125 mg/m2 paclitaxel in a nanoparticle composition to the individual. 36. The method of claim 35, wherein the method comprises administering about 1000 to about 2000 mg/m2 gemcitabine to the individual. 37. The method of claim 36, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 4:1 to about 10:1. 38. The method of claim 37, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 9:1. 39. The method of claim 21, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 4:1 to about 10:1. 40. The method of claim 39, wherein the weight ratio of the albumin and the paclitaxel in the paclitaxel composition is about 9:1. 41. The method of claim 1, wherein the pancreatic cancer is advanced pancreatic cancer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (76)
Baca, Manuel; Wells, James A., Anti-VEGF antibodies.
Muller Marcel,CHX ; Geiger Thomas,DEX ; Altmann Karl-Heinz,CHX ; Fabbro Doriano,CHX ; Dean Nicholas M. ; Monia Brett ; Bennett Clarence Frank, Combination for treatment of proliferative diseases.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Composition useful for in vivo delivery of biologics and methods employing same.
De, Tapas; Desai, Neil P.; Yang, Andrew; Yim, Zachary; Soon-Shiong, Patrick, Compositions and methods for preparation of poorly water soluble drugs with increased stability.
De, Tapas; Desai, Neil P.; Yang, Andrew; Yim, Zachary; Soon-Shiong, Patrick, Compositions and methods for preparation of poorly water soluble drugs with increased stability.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Desai, Neil P.; Tao, Chunlin; Yang, Andrew; Louie, Leslie; Soon-Shiong, Patrick, Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof.
Bendig Mary M. (London GBX) Kettleborough Catherine A. (Herts GBX) Saldanha Jose (Middlesex GBX), Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell.
Goldman, Mitchel P.; Weiss, Robert A.; Zikorus, Arthur W.; Chandler, James G., Method and apparatus for applying energy to biological tissue including the use of tumescent tissue compression.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Method for the preparation of fluorocarbon-containing polymeric shells for medical imaging.
Brown Paul A. ; Bursten Stuart L. ; Rice Glenn C. ; Singer Jack W., Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF, and VEGF.
Heimbrook David C. (Ringoes NJ) Oliff Allen I. (Gwynedd Valley PA) Stirdivant Steven M. (Warrington PA) Ahern Janet (Horsham PA), Method of treating bladder cancer cells.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champagne IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champagne IL) Desai Neil P. (Los Angeles CA), Methods for in vivo delivery of nutriceuticals and compositions useful therefor.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of blood substitutes for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champagne IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champagne IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of immunostimulating agents for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of nucleic acids for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of pharmaceutically active agents for in vivo delivery.
Bagchi Pranab (Webster NY) Stewart Robert C. (Spencerport NY) McIntire Gregory L. (West Chester PA) Minter John R. (Rochester NY), Microprecipitation of micro-nanoparticulate pharmaceutical agents.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Non-fluorinated polymeric shells for medical imaging.
Zenke Gerhard,DEX ; Schuurman Hendrik,CHX ; Haeberlin Barbara,CHX ; Meinzer Armin,DEX, Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof.
Desai Neil P. ; Tao Chunlin ; Yang Andrew ; Louie Leslie ; Zheng Tianli ; Yao Zhiwen ; Soon-Shiong Patrick ; Magdassi Shlomo,ILX, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Desai, Neil P.; Tao, Chunlin; Yang, Andrew; Louie, Leslie; Yao, Zhiwen; Soon-Shiong, Patrick; Magdassi, Shlomo, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Magdassi Shlomo,ILX ; Yang Andrew ; Tao Chunlin ; Desai Neil P. ; Yao Zhiwen ; Soon-Shiong Patrick, Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof.
Magdassi, Shlomo; Yang, Andrew; Tao, Chunlin; Desai, Neil P.; Yao, Zhiwen; Soon-Shiong, Patrick, Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof.
De, Tapas; Desai, Neil P; Yang, Andrew; Yim, Zachary; Soon-Shiong, Patrick, Compositions and methods for preparation of poorly water soluble drugs with increased stability.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.